Carregant...
Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis Patients
The effect of switching from originator infliximab to biosimilar infliximab in patients with sarcoidosis is unknown. The objective of this study is to investigate the effect of switching from Remicade(®) or Inflectra(®) to Flixabi(®) in patients with severe refractory sarcoidosis. This single center...
Guardat en:
| Publicat a: | Cells |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7922542/ https://ncbi.nlm.nih.gov/pubmed/33669641 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells10020441 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|